Key result
Astragaloside IV prevented kidney injury caused by iatrogenic hyperinsulinemia in diabetic rats by inhibiting oxidative stress and inflammation, downregulating ERK1/2 activation, and upregulating TRPC6 expression.
Why the study?
Does astragaloside IV prevent kidney injury in a diabetic rat model with iatrogenic hyperinsulinemia?
Population
48 male Sprague-Dawley rats with streptozotocin-induced diabetes and iatrogenic hyperinsulinemia.
Comparison
Astragaloside IV at 2.5, 5, or 10 mg/kg/day via… vs Iatrogenic hyperinsulinemic rats receiving…
Design
Preclinical, randomly divided, pathologist blind to the experimental profile…
Follow-up
12 weeks
Authors
Loading...
Hypothesis-generating in diabetic rat models; human trials required before any clinical consideration.
Does astragaloside IV prevent kidney injury in a diabetic rat model with iatrogenic hyperinsulinemia?
p-value: p=<0.01
Astragaloside IV attenuates kidney injury in a diabetic rat model of iatrogenic hyperinsulinemia by inhibiting oxidative stress and inflammation.
He et al. (2017) studied Diabetic nephropathy and iatrogenic hyperinsulinemia (n=48). Astragaloside IV vs. Saline (control) and Tempol was evaluated on Kidney injury markers (albuminuria, mesangial cell proliferation, basement membrane thickening, and podocyte foot process effacement) (p=<0.01). Astragaloside IV prevented kidney injury caused by iatrogenic hyperinsulinemia in diabetic rats by inhibiting oxidative stress and inflammation, downregulating ERK1/2 activation, and upregulating TRPC6 expression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: